 |
|
|
|
||||||
|
| |
Leaders in synthetic micropeptides
Lytix Biopharma AS is a privately-owned pharmaceutical company focussed on anti-microbials and cancer therapeutics. We specialize in synthetic micro-peptides with novel membrane-lysing mechanisms of action. Over the last three years, we have developed a fully integrated approach. First class drug discovery and strong competencies in medicinal chemistry and clinical development have been combined with unrivalled expertise in peptidomimetics and peptide drug design. This has resulted in an exciting pipeline - comprising both ultra-broad spectrum antimicrobials and an entirely new class of dual-action cancer therapeutics. For potential partners, we now offer attractive co-development and licensing opportunities. |
|
 Tromsø, May 28, 2008:
Lytix Establishes New Board of Directors- The Scandinavian-based drug development company Lytix Biopharma AS announces the establishment of a new Board of Directors during the Annual General Assembly meeting of shareholders. Tromsø, June 12, 2008:
Lytix to take their lead anticancer compound, Oncopore into clinicTromsø, November 28, 2007:
Prospectus Private Placement MNOK 50Tromsø, September 20, 2007:
Lytix to take lead antimicrobial compound into clinicTromsø, October 23, 2006:
Lytix announces antimicrobial drug leads ready for licensingTromsø, June 01, 2006:
Lytix Biopharma AS achieves promising resultsTromsø, April 30, 2006:
Lytix Biopharma AS has successfully closed a private placement |
||||
       |
